Self Assessment Question 1

Similar documents
To understand the formulary process from the hospital perspective

Cytochrome P450 Drug Interaction Table Flockhart Table

Drug Interactions Year 2 Clinical Pharmacology

Who remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?

Psychotropic Drug Interactions Over the past 2 decades:

Pharmacogenetic Testing in Psychiatry Jose de Leon, MD ( )

Mental Health DNA Insight WHITE PAPER

ETHNICITY AND PSYCHOTROPIC RESPONSE

SUMMARY OF PRODUCT CHARACTERISTICS

Drug Interactions Keeping it all Straight. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre

Drug Interactions: Let me count the ways

AFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June

Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence

Pharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne

Drug-Drug Interactions in Psychiatry

Index. Bulimia, 13 Bupropion, 12, 51 Buspirone, 81

SMOKING AND DRUG INTERACTIONS

Objectives. Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner

Drug-drug interactions in the elderly

Pharmacogenomics and Clinical Practice: Ready for Prime Time?

Drug Interactions for the Emergency Physician. Lisa Thurgur

OBJECTIVES. Key issues in geriatric pharmacology. Effects of age on pharmacokinetics and pharmacodynamics

PHARMACOTHERAPY IN THE OLDER PERSON NAMIRAH JAMSHED M.B;B.S ASSOCIATE PROFESSOR UTSW MEDICAL CENTER DALLAS

Pharmacogenomics and Clinical Practice: Ready for Prime Time? Disclosures. Elder-Friendly Futures Conference 2013 A UW Gerontology Conference

Drug Interactions Year 2 Clinical Pharmacology

ESPEN Congress The Hague 2017

Drug Interactions: Definition

Prescribing Drugs to the Elderly

Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data

Title of Lecture: Pharmacokinetics II Metabolism and Excretion (Problem 17, Lecture 2, 2009)

Farmacologia di genere. Prof. Alberto Corsini Università degli Studi di Milano

WHAT S NEW. Vilazodone (Viibryd ) Vilazodone - Dosing ANTIDEPRESSANT UPDATE: What s New? The Cardiac Debate The Efficacy Debate?Pharmacogenomics?

SUMMARY OF PRODUCT CHARACTERISTICS

The Case of Libby Zion and Dangerous Drug Interactions

Polypharmacy and Common Drug Interactions in Geriatric Patients

Manual of Clinical Psychopharmacology

Quetiapine Case 1 Warfarin Jose de Leon, MD

Quetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD

12/9/2015. Drug Interactions. Sarah Robertson, Pharm.D. Director, Department of Clinical Pharmacology Vertex Pharmaceuticals Inc.

Undesirable drug interaction in palliative medicine

5th European Summer School. Drug interactions. therapeutic Information

AGS AN APPROACH TO MEDICATION MANAGEMENT IN OLDER ADULTS

Interactions Between Herbal Medicines and Prescribed Drugs

PROGRAM General Information

Introduction to Drug Treatment

Drug Interactions. Drug Interactions: Definition

CYP2D6: mirtazapine 2001/2002/2003

Linda Sobeski Farho, PharmD, BCPS Assistant Professor, Pharmacy Practice UNMC College of Pharmacy Critical Issues in Geriatrics June 24, 2010

Recommended dosing for pediatric patients (6 months to 12 years of age) 1. Dose based on lopinavir component* 1.25 ml ml

Ingrezza. (valbenazine) New Product Slideshow

Palliative Care Drug Plan (Plan P) Formulary List of drugs PharmaCare covers

Pharmacogenomics and Cultural Issues! Y. W. Francis Lam, Pharm.D., FCCP!

Drug Interactions. Stephen Kravcik MD FRCPC Division of General Medicine University of Ottawa

Concomitant antiretroviral therapy : Avifanz must be given in combination with other antiretroviral medications.

They deserve personalized treatment

Study Guidelines for Quiz #1

Annotation Guidelines

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants

Two decades of clinical pharmacogenetic testing - Where do we stand?

Initiation Guide. Images not actual size.

COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE INVESTIGATION OF DRUG INTERACTIONS

CONTRAINDICATIONS TABLE

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

3. P450 Drug Metabolism DDIs: Induction

Pharmacogenomics of Medications for Pain and Major Depression: Promise and Peril

Psychiatric Transplant Evaluation

Drug drug interactions highlighting P450 Cytochromes. Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 29, 2015 National

Carey Crill, MSN, CPNP, CPMHNP And Julie Schrader, MSN, CPMHNP

Herbal/Drug Interactions. Gary W. Elmer 11/12/09

Therapeutic drug monitoring. Department of Clinical Pharmacology, Wrocław Medical University

Drug Interactions and ORT

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

2/25/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY OVERALL PRESCRIBING

Appendix IV - Prescribing Guidance for Apixaban

Pharmacogenomics of Antidepressant Medications

2/26/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY

Pharmacology in the Elderly

Medicine Related Falls Risk Assessment Tool (MRFRAT)

FDA s Clinical Drug Interaction Studies Guidance (2017 Draft Guidance)

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. Tivozanib. PROTOCOL REF: MPHATIVOUR (Version No: 1.

Smoking Cessation Pharmacotherapy Guidelines

12/19/16. Disclosures

Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP

Supplementary Online Content

Aging and Geriatric Assessment March 31, 2008 Sharon Leigh, Pharm D. BCPS Providence ElderPlace

Understanding the Drug Drug Interaction

North Dakota Medicaid. Drug Utilization Review Board. Drug Class Review

SGEC Webinar Handouts 3/8/2013 FAMILIES. Please visit our website for more information

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY

CULTURAL ASPECTS OF THE PHARMACOLOGICAL MANAGEMENT OF DEMENTIA. SGEC Webinar Handouts 3/8/2013

Drug Intractions Alessandro Nobili Luca Pasina Claudia Braun What does the term drug interaction mean?

Disclosure. Objectives: Technician. Objectives: Pharmacist. Diagnostic and Statistical Manual (DSM-V) The Face of Mental Illness 7/25/2015

Effects of Liver Disease on Pharmacokinetics

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

Core Safety Profile: Midazolam Route of Administration Tablets Procedure: FR/H/PSUR/0026/001 Decemebr 2011

O ut of the pipeline >

Katee Kindler, PharmD, BCACP

Are health care systems ready to deliver pharmacogenetics as standard of care? Predicting the needs and setting the strategies

Transcription:

Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1

Self Assessment Question 1 Compared to the rate of ADRs among adults age 20-29, the rate among adults age 80+ is which of the following: A. Similar B. Twice as great C. Greater than 5 x as frequent D. Greater than 10 x as frequent 2

Self Assessment Question 2 Commonly prescribed psychiatric medications are substrates of which of the following C450 enzymes? A. 1A2 B. 2D6 C. 3A4 D. All of the above 3

Self Assessment Question 3 Which of the following 3A inhibitors can be associated with significant drug/drug interactions when co-administered with a 3A substrate? A. Ketoconazole B. Erythromycin C. Calcium antagonists D. Any of the above 4

Self Assessment Question 4 Which of the following medications has anticholinergic properties? A. Furosemide B. Warfarin C. Ranitidine D. Digoxin E. All the above 5

Self Assessment Question 5 The risk of drug/drug interactions is increased by which of the following? A. Narrow therapeutic index of co-administered agent B. Highly potent co-administered enzyme inducer or inhibitor C. Greater sensitivity to adverse effects in elderly patients D. Co-administration of multiple drugs E. All the above 6

Major Teaching Points Elderly patients are highly vulnerable to drug/drug interactions Two important types of drug/drug interactions to understand and prevent are: Pharmacokinetic interactions based on drug metabolism through the cytochrome P450 system Pharmacodynamic interactions based on additive serum anticholinergicity 7

Brief Outline Adverse drug interactions relationship to age, location, number of prescribed drugs Cytochrome P450 drug interactions Drug interactions based on additive serum anticholinergicity Coping with drug/drug interactions Suggested readings 8

ADRs per 10,000 Population Adverse Drug Reactions (ADRs) as a Function of Increasing Age 60 50 40 30 20 10 0 1 (infancy) 20-29 40-49 60-69 80+ Age (y) Ghose K. Drugs Aging. 1991;1:2-5. 9

Adverse Drug Reactions in the Nursing Home Psychoactive medications (antipsychotics, antidepressants, and sedatives/hypnotics) and anticoagulants were the medications most often associated with preventable ADRs Gurwitz JH, et al. Am J Med. 2000;109:87-94. 10

Patients (%) Relationship Between Prescribing Rate and Prevalence of Potential Drug Interactions 100 90 80 70 60 50 40 30 20 10 0 % of Patients With Interacting Combinations 0 1 2 3 4 5 6 7 8 9 10 11 12 No. of Drugs Prescribed per Patient Nolan L, O Malley K. Age Ageing. 1989;18:52-56. 11

Clinical Dilemma Number of possible drug interactions too large to memorize Difficult to determine which interactions are important Conflicting promotional claims 12

Cytochrome P-450 Enzyme Subtypes CYP1A2 CYP2E1 CYP2C CYP2D6 CYP3A4 13

CYP isoform Representative substrates 1A2 Caffeine, theophylline, tacrine 2B6 2C9 2C19 2D6 2E1 3A Propofol, bupropion Phenytoin, S-warfarin, tolbutamide, NSAIDs Omeprazole (partial contributor to many) Some CNS and cardiac drugs Fluranes, chlorzoxane (many) 14

CYP3A High abundance Present in G.I Tract No polymorphism, but high individual variability 15

CYP3A Substrates Complete Benzodiazepines (short t 1/2 ) Buspirone Trazodone Nefazodone Cyclosporine Statins Calcium antagonists Quinidine Protease Inhibitors Sildenafil Partial Zolpidem Amitriptyline Imipramine Sertraline Citalopram Diazepam Clozapine 16

CY3A Inhibitors High Risk Ketoconazole Itraconazole Nefazodone Ritonavir (acute) Erythromycin Clarithromycin Calcium Antagonists Moderate Risk Fluconazole Fluvoxamine Fluoxetine Grapefruit juice Other HIV PIs Delavirdine Cimetidine 17

CYP3A Inducers Rifampin Barbiturates Carbamazepine Ritonavir (chronic) Nevirapine Hypericum perforatum (St. John s Wort) 18

CYP3A4: Verapamil Verapamil Clearance (ml/min/kg) 29 27 25 23 21 19 17 15 13 11 9 7 5 20 30 40 50 60 70 80 90 Age (y) Racemic verapamil clearance data are plotted versus age for women (solid circles) and men (open circles). The solid line represents the regression of clearance versus age relationship in women (P <.004) and the broken line represents the regression of clearance versus age in men (regression not significant). 19 Schwartz JB, et al. Clin Pharmacol Ther. 1994;55:509-517.

St. John s Wort Induces P-glycoprotein Digoxin by 30% Induces CYP3A4 Indinavir Cyclosporine Statins Ruschitzka F, et al. Lancet. 2000;355(9203):548-549. Piscitelli SC, et al. Lancet. 2000;355(9203):547-548. 20

CYP1A2 Phenotyping (Caffeine) Results Before and After Estrogen Treatment of Healthy Postmenopausal Women Paraxanthine/Caffeine Ratio 1.0 Before Estrogen After Estrogen 0.8 0.6 0.4 0.2 0.0 Patients Pollock BG, et al. J Clin Psychopharmacol. 2000;20:137-140. 21

Cytochrome P-450: Enzymes and Selected Substrates 1A2 2C 2D6 3A4 Theophylline Phenytoin Codeine Antihistamines Warfarin Warfarin Venlafaxine Calcium channel blockers Antipsychotics Amitriptyline Trazodone Carbamazepine Benzodiazepines Clomipramine Risperidone Cisapride Fluvoxamine Omeprazole Haloperidol Corticosteroids Tramadol -Blockers Cyclosporine Fentanyl Protease inhibitors Statins Triazolobenzodiazepines Michalets EL. Pharmacotherapy. 1998;18:84-112. Cupp MJ, Tracy TS. Am Fam Physician. 1998;57:107-116. 22

Inhibition of Human Cytochrome P-450 Isoenzymes by Newer Antidepressants Cytochrome P-450 Isoenzyme Antidepressant 1A2 2C9 2C19 2D6 2E1 3A Fluoxetine + ++ + to ++ +++ + Norfluoxetine + ++ + to ++ +++ ++ Sertraline + + + to ++ + + Desmethylsertraline + + + to ++ + + Paroxetine + + + +++ + Fluvoxamine +++ ++ +++ + ++ Citalopram + 0 0 0 0 0 R-Desmethylcitalopram 0 0 0 + 0 0 Escitalopram 0 0 0 0 0 0 S-Desmethylcitalopram 0 0 0 0 0 0 Nefazodone 0 0 0 0 +++ Triazoledione 0 0 0 0 + Hydroxynefazodone 0 0 0 0 +++ Venlafaxine 0 0 0 0 0 O-Desmethylvenlafaxine 0 0 0 0 0 Mirtazapine 0 + 0 0 = minimal or zero inhibition. + = mild inhibition. ++ = moderate inhibition. +++ = strong inhibition. = no data available. Greenblatt DJ, et al. J Clin Psychiatry. 1998;59(suppl 15):19-27. von Moltke LL, et al. Drug Metab Disposition. 2001;29:1102-1108. 23

Incidence of Bleeding During Anticoagulant Therapy 100 80 75 years 65-74 years < 65 years Major Bleeding (%) 60 40 20 Years 0 0 1 2 3 4 N = 660 231 189 114 64 24 Beyth RJ, Schorr RI. Drugs Aging. 1999;14:231-239.

American Medical Directors Association Top 10 Drug Interactions Warfarin with: NSAIDs Macrolides Phenytoin Sulfa Drugs Quinolones 25

Warfarin Metabolism S-warfarin CYP2C9 Fluoxetine Fluvoxamine (Sertraline) (Paroxetine) R-warfarin (major pathway) CYP1A2 Fluvoxamine (Fluoxetine) (Sertraline) (Paroxetine) R-warfarin (minor pathway) CYP2C19 & CYP3A4 26

Platelet Activation in Depressed Patients With Ischemic Heart Disease After Paroxetine or Nortriptyline Treatment PF4 (IU/mL) 160 140 120 100 80 60 40 20 0 * * Baseline Week 1 Week 3 Week 6 * Effect of paroxetine ( ) and nortriptyline ( ) on PF4 plasma levels in depressed patients with ischemic heart disease. Data presented are mean ± SEM *P <.05 versus baseline levels. PF4 = platelet factor 4. Pollock BG, et al. J Clin Psychopharmacol. 2000;20:137-140. 27

Anticholinergic Medications Commonly Prescribed in the Elderly Commonly Prescribed in the Elderly Furosemide Digoxin Theophylline Warfarin Prednisolone Triamterene and hydrochlorothiazide Nifedipine Isosorbide Codeine Cimetidine Captopril Ranitidine Dipyridamole Tune L, et al. Am J Psychiatry. 1992;149:1393-1394. 28

Age, Sex, Education, Number of Medications, MMSE score, and SA (N = 201) Mean (SD) Age 78.2 (5.2) Female (N, %) 122 (60.7%) Education (< high school) 38.3 % Number of Medications 5.2 (3.4) Number of Anticholinergic Medications 0.91 (1.23) MMSE 26.8 (3.5) SA (pmol/ml) Mean (SD) 1.45 (1.10) Median (Range) 1.25 [0-5.70] MMSE = Mini-Mental State Examination. SA = serum anticholinergicity. 29 Mulsant BH, Pollock BG, et al. Am J Ger Psychiatry. 2002;10(suppl):58.

Logistic Regressions: SA as a Continuous Variable OR 95% CI Age 1.20 (1.09, 1.32) Sex Male 1.00 --- Female 1.15 (0.37, 3.57) Education < high school 1.00 --- > high school 0.39 (0.13,1.21) # of Rx 0-3 1.00 --- 4-6 1.46 (0.39,5.44) > 6 1.21 (0.29,5.05) SA 16.71 (2.02, 138.29) SA = serum anticholinergicity. Mulsant BH, Pollock BG, et al. Am J Ger Psychiatry. 2002;10(suppl):58. 30

Elderly Are More Difficult to Treat Safely Pharmacokinetic changes result in higher and more variable drug concentrations The elderly often take multiple medications Greater sensitivity exists to a given drug concentration Homeostatic reserve may be impaired 31

When To Worry About Drug Interactions Narrow therapeutic index of victim Highly potent inducer or inhibitor 32

Coping With Drug Interactions Anticipation and prevention Highly potent inducer/inhibitor Narrow therapeutic index of victim Victims dependent on one metabolic enzyme/transport protein 33

Coping With Drug Interactions Recognize interaction potential of nondrugs (herbals) Keep knowledge base current Consider interactions whenever the clinical picture unexpectedly changes 34

Suggested Readings Pollock BG: Geriatric Psychiatry: Psychopharmacology: General Principles. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry/VII. Baltimore: Williams & Wilkins 2000 pp 3086-3090. DeVane CL, Pollock BG: Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry 60[suppl 20]:38-44, 1999. 35

Self Assessment Question 1 Compared to the rate of ADRs among adults age 20-29, the rate among adults age 80+ is which of the following: A. Similar B. Twice as great C. Greater than 5 x as frequent D. Greater than 10 x as frequent 36

Self Assessment Question 2 Commonly prescribed psychiatric medications are substrates of which of the following C450 enzymes? A. 1A2 B. 2D6 C. 3A4 D. All of the above 37

Self Assessment Question 3 Which of the following 3A inhibitors can be associated with significant drug/drug interactions when co-administered with a 3A substrate? A. Ketoconazole B. Erythromycin C. Calcium antagonists D. Any of the above 38

Self Assessment Question 4 Which of the following medications has anticholinergic properties? A. Furosemide B. Warfarin C. Ranitidine D. Digoxin E. All the above 39

Self Assessment Question 5 The risk of drug/drug interactions is increased by which of the following? A. Narrow therapeutic index of co-administered agent B. Highly potent co-administered enzyme inducer or inhibitor C. Greater sensitivity to adverse effects in elderly patients D. Co-administration of multiple drugs E. All the above 40

Self Assessment Question Answers 1. C 2. D 3. D 4. E 5. E 41